ProMIS Neurosciences Inc.

The momentum for this stock is not very good. ProMIS Neurosciences Inc. is not a good growth stock. ProMIS Neurosciences Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in ProMIS Neurosciences Inc..
Log in to see more information.
PMN Fundamental Data by TradingView

News

ProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cog
ProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cog

Globe Newswire CAMBRIDGE, Massachusetts and TORONTO, Ontario, Sept. 12, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of...\n more…

ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Globe Newswire CAMBRIDGE, Massachusetts and TORONTO, Ontario, Sept. 05, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of...\n more…

ProMIS Neurosciences files to sell 56.51M common shares for holders
ProMIS Neurosciences files to sell 56.51M common shares for holders

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

ProMIS Neurosciences, Inc. (NASDAQ:PMN) Director Buys $12,500.00 in Stock
ProMIS Neurosciences, Inc. (NASDAQ:PMN) Director Buys $12,500.00 in Stock

Ticker Report ProMIS Neurosciences, Inc. (NASDAQ:PMN - Get Free Report) Director Patrick D. Kirwin acquired 10,000 shares of the stock in a transaction dated Wednesday, August 14th. The shares were bought at an...\n more…

PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q2 2024
PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q2 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nPMN stock results show that ProMIS Neurosciences beat analyst estimates for earnings per share the second quarter of 2024.\nThe post PMN...\n more…

ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights
ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights

Globe Newswire Reported positive topline data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer's disease that met objectives for tolerability, safety and pharmacokinetics Secured...\n more…